{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T06:03:57Z","timestamp":1794895437505,"version":"4.9.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["FLUME15A0"],"award-info":[{"award-number":["FLUME15A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR001450"],"award-info":[{"award-number":["UL1 TR001450"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 DK089507"],"award-info":[{"award-number":["P30 DK089507"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016739","name":"BioFire Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["FLUME15A0"],"award-info":[{"award-number":["FLUME15A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000897","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR001450"],"award-info":[{"award-number":["UL1 TR001450"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 DK089507"],"award-info":[{"award-number":["P30 DK089507"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"BioFire Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Rates of viral respiratory infection (VRI) are similar in people with cystic fibrosis (CF) and the general population; however, the associations between VRI and CF pulmonary exacerbations (PEx) require further elucidation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine VRI prevalence during CF PEx and evaluate associations between VRI, clinical presentation, and treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The STOP2 (Standardized Treatment of Pulmonary Exacerbations II) study was a multicenter randomized trial to evaluate different durations of intravenous antibiotic therapy for PEx. In this ancillary study, participant sputum samples from up to three study visits were tested for respiratory viruses using multiplex polymerase chain reactions. Baselines and treatment-associated changes in mean lung function (percent predicted forced expiratory volume in 1\u2009s), respiratory symptoms (Chronic Respiratory Infection Symptom Score), weight, and C-reactive protein were compared as a function of virus detection. Odds of PEx retreatment within 30\u2009days and future PEx hazard were modeled by logistic and Cox proportional hazards regression, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1,254 sputum samples from 621 study participants were analyzed. One or more respiratory viruses were detected in sputum samples from 245 participants (39.5%). Virus-positive participants were more likely to be receiving CF transmembrane conductance regulator modulator therapy (45% vs. 34%) and\/or chronic azithromycin therapy (54% vs. 44%) and more likely to have received treatment for nontuberculous Mycobacterium infection in the preceding 2\u2009years (7% vs. 3%). At study visit 1, virus-positive participants were more symptomatic (mean Chronic Respiratory Infection Symptom Score, 53.8 vs. 51.1), had evidence of greater systemic inflammation (log10 C-reactive protein concentration, 1.32 log10 mg\/L vs. 1.23 log10 mg\/L), and had a greater drop in percent predicted forced expiratory volume in 1\u2009second from the prior 6-month baseline (5.8 vs. 3.6). Virus positivity was associated with reduced risk of future PEx (hazard ratio, 0.82; 95% confidence interval, 0.69\u20130.99; P\u2009=\u20090.034) and longer median time to next PEx (255 d vs. 172 d; P\u2009=\u20090.021) compared with virus negativity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>More than one-third of STOP2 participants treated for a PEx had a positive test result for a respiratory virus with more symptomatic initial presentation compared with virus-negative participants, but favorable long-term outcomes. More refined phenotyping of PEx, taking VRIs into account, may aid in optimizing personalized management of PEx.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT02781610).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1513\/annalsats.202306-576oc","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T15:31:16Z","timestamp":1699975876000},"page":"595-603","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":20,"title":["Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations"],"prefix":"10.1093","volume":"21","author":[{"given":"Christina S.","family":"Thornton","sequence":"first","affiliation":[{"name":"Department of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay J.","family":"Caverly","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Kalikin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Carmody","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"McClellan","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"LeBar","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don B.","family":"Sanders","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Indiana University, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0025-2422","authenticated-orcid":false,"given":"Natalie E.","family":"West","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H.","family":"Goss","sequence":"additional","affiliation":[{"name":"Department of Medicine and"},{"name":"Department of Pediatrics, University of Washington, Seattle, Washington"},{"name":"CF Therapeutics Development Network Coordinating Center, Seattle Children\u2019s Research Institute, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Flume","sequence":"additional","affiliation":[{"name":"Department of Medicine and"},{"name":"Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya L.","family":"Heltshe","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Washington, Seattle, Washington"},{"name":"CF Therapeutics Development Network Coordinating Center, Seattle Children\u2019s Research Institute, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald R.","family":"VanDevanter","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"LiPuma","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,1]]},"reference":[{"key":"2026012203144351500_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/thoraxjnl-2013-204000","article-title":"Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis","volume":"69","author":"Flight","year":"2014","journal-title":"Thorax"},{"key":"2026012203144351500_bib2","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/cid\/cix203","article-title":"Cystic fibrosis pulmonary exacerbations attributable to respiratory syncytial virus and influenza: a population-based study","volume":"64","author":"Somayaji","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026012203144351500_bib3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jcv.2014.02.005","article-title":"Virus and cystic fibrosis: rhinoviruses are associated with exacerbations in adult patients","volume":"60","author":"Goffard","year":"2014","journal-title":"J Clin Virol"},{"key":"2026012203144351500_bib4","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3201\/eid1606.100063","article-title":"Rhinovirus C and respiratory exacerbations in children with cystic fibrosis","volume":"16","author":"de Almeida","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"2026012203144351500_bib5","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1183\/09031936.00229114","article-title":"Pathogenicity of individual rhinovirus species during exacerbations of cystic fibrosis","volume":"45","author":"Shah","year":"2015","journal-title":"Eur Respir J"},{"key":"2026012203144351500_bib6","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1055\/s-0042-1758728","article-title":"Respiratory viruses and cystic fibrosis","volume":"44","author":"Brackenborough","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"2026012203144351500_bib7","doi-asserted-by":"crossref","first-page":"e72174","DOI":"10.1371\/journal.pone.0072174","article-title":"Comparative evaluation of six commercialized multiplex PCR kits for the diagnosis of respiratory infections","volume":"8","author":"Pillet","year":"2013","journal-title":"PLoS One"},{"key":"2026012203144351500_bib8","first-page":"639","article-title":"The role of multiplex PCR in respiratory tract infections in children","volume":"111","author":"Krause","year":"2014","journal-title":"Dtsch Arztebl Int"},{"key":"2026012203144351500_bib9","doi-asserted-by":"crossref","first-page":"637559","DOI":"10.3389\/fmolb.2021.637559","article-title":"Virus detection: a review of the current and emerging molecular and immunological methods","volume":"8","author":"Cassedy","year":"2021","journal-title":"Front Mol Biosci"},{"key":"2026012203144351500_bib10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jcf.2012.04.006","article-title":"Role of respiratory viruses in pulmonary exacerbations in children with cystic fibrosis","volume":"11","author":"Asner","year":"2012","journal-title":"J Cyst Fibros"},{"key":"2026012203144351500_bib11","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1080\/1040841X.2017.1297763","article-title":"Viruses in cystic fibrosis patients\u2019 airways","volume":"43","author":"Billard","year":"2017","journal-title":"Crit Rev Microbiol"},{"key":"2026012203144351500_bib12","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1128\/CMR.00068-09","article-title":"The changing microbial epidemiology in cystic fibrosis","volume":"23","author":"Lipuma","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"2026012203144351500_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jcf.2005.05.011","article-title":"Viral respiratory infections in cystic fibrosis","volume":"4","author":"van Ewijk","year":"2005","journal-title":"J Cyst Fibros"},{"key":"2026012203144351500_bib14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/INF.0000000000001014","article-title":"Frequency and duration of rhinovirus infections in children with cystic fibrosis and healthy controls: a longitudinal cohort study","volume":"35","author":"Dijkema","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"2026012203144351500_bib15","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/ppul.20517","article-title":"Viral and atypical bacterial infections in the outpatient pediatric cystic fibrosis clinic","volume":"41","author":"Olesen","year":"2006","journal-title":"Pediatr Pulmonol"},{"key":"2026012203144351500_bib16","doi-asserted-by":"crossref","first-page":"e78583","DOI":"10.1371\/journal.pone.0078583","article-title":"Influenza A(H1N1)pdm09 and cystic fibrosis lung disease: a systematic meta-analysis","volume":"9","author":"Renk","year":"2014","journal-title":"PLoS One"},{"key":"2026012203144351500_bib17","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1542\/peds.2007-3139","article-title":"Prevalence and impact of respiratory viral infections in young children with cystic fibrosis: prospective cohort study","volume":"122","author":"van Ewijk","year":"2008","journal-title":"Pediatrics"},{"key":"2026012203144351500_bib18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jcf.2007.12.002","article-title":"The role of respiratory viruses in cystic fibrosis","volume":"7","author":"Wat","year":"2008","journal-title":"J Cyst Fibros"},{"key":"2026012203144351500_bib19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1542\/peds.103.3.619","article-title":"Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis","volume":"103","author":"Hiatt","year":"1999","journal-title":"Pediatrics"},{"key":"2026012203144351500_bib20","first-page":"662","article-title":"The effect of respiratory viral infections on patients with cystic fibrosis","volume":"143","author":"Ramsey","year":"1989","journal-title":"Am J Dis Child"},{"key":"2026012203144351500_bib21","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1136\/thx.51.11.1115","article-title":"Effects of upper respiratory tract infections in patients with cystic fibrosis","volume":"51","author":"Collinson","year":"1996","journal-title":"Thorax"},{"key":"2026012203144351500_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/adc.73.2.117","article-title":"Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis","volume":"73","author":"Smyth","year":"1995","journal-title":"Arch Dis Child"},{"key":"2026012203144351500_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jcf.2013.06.004","article-title":"The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation","volume":"13","author":"Etherington","year":"2014","journal-title":"J Cyst Fibros"},{"key":"2026012203144351500_bib24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1017\/S0950268807008278","article-title":"Ten years of viral and non-bacterial serology in adults with cystic fibrosis","volume":"136","author":"Clifton","year":"2008","journal-title":"Epidemiol Infect"},{"key":"2026012203144351500_bib25","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1136\/thx.44.9.739","article-title":"Infective respiratory exacerbations in young adults with cystic fibrosis: role of viruses and atypical microorganisms","volume":"44","author":"Ong","year":"1989","journal-title":"Thorax"},{"key":"2026012203144351500_bib26","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1164\/rccm.202102-0461OC","article-title":"A randomized clinical trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment","volume":"204","author":"Goss","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"S36","key":"2026012203144351500_bib27","first-page":"295","article-title":"Validation of a novel patient-reported respiratory symptoms instrument in cystic fibrosis: CFRSD-CRISS [abstract]","volume":"48","author":"Goss","year":"2013","journal-title":"Pediatric Pulmonol"},{"key":"2026012203144351500_bib28","author":"BioFire Diagnostics","year":"2020"},{"key":"2026012203144351500_bib29","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jcf.2021.11.009","article-title":"Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation","volume":"21","author":"Sanders","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026012203144351500_bib30","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jcf.2021.12.003","article-title":"C-reactive protein (CRP) as a biomarker of pulmonary exacerbation presentation and treatment response","volume":"21","author":"VanDevanter","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026012203144351500_bib31","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jcf.2022.04.006","article-title":"Antipseudomonal treatment decisions during CF exacerbation management","volume":"21","author":"VanDevanter","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026012203144351500_bib32","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1093\/jpids\/piac062","article-title":"The elusive role of airway infection in cystic fibrosis exacerbation","volume":"11","author":"Caverly","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2026012203144351500_bib33","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1513\/AnnalsATS.202111-1266OC","article-title":"Acute pulmonary exacerbation phenotypes in patients with cystic fibrosis","volume":"19","author":"Carter","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203144351500_bib34","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1002\/ppul.25627","article-title":"Review of CFTR modulators 2020","volume":"56","author":"Goetz","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"2026012203144351500_bib35","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jcf.2014.11.009","article-title":"Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations","volume":"14","author":"Chin","year":"2015","journal-title":"J Cyst Fibros"},{"key":"2026012203144351500_bib36","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/cells11071243","article-title":"CFTR modulator therapies: potential impact on airway infections in cystic fibrosis","volume":"11","author":"Saluzzo","year":"2022","journal-title":"Cells"},{"key":"2026012203144351500_bib37","doi-asserted-by":"crossref","first-page":"548613","DOI":"10.3389\/fcimb.2021.548613","article-title":"Changes in the cystic fibrosis airway microbiome in response to CFTR modulator therapy","volume":"11","author":"Yi","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2026012203144351500_bib38","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.3390\/ijms23073513","article-title":"The effect of CFTR modulators on airway infection in cystic fibrosis","volume":"23","author":"Harvey","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026012203144351500_bib39","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.3389\/fimmu.2018.03067","article-title":"Viral-bacterial co-infections in the cystic fibrosis respiratory tract","volume":"9","author":"Kiedrowski","year":"2018","journal-title":"Front Immunol"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/4\/595\/66009562\/annalsats_21_4_595.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/21\/4\/595\/66009562\/annalsats_21_4_595.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:15:44Z","timestamp":1769069744000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/21\/4\/595\/8382014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,1]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202306-576oc","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,4,1]]},"assertion":[{"value":"2023-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}